Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.

Journal of cardiovascular medicine (Hagerstown, Md.) - 1 Dec 2013

Valgimigli Marco

Abstract excerpt

Some patients with acute coronary syndromes and/or who are undergoing percutaneous coronary interventions (PCI) remain at risk for cardiovascular events despite antiplatelet treatment with clopidogrel. This may be due, at least in part, to high residual on-treatment platelet reactivity (PR). Given the potential seriousness of an incomplete response to treatment, there is a need for a simple, rapid and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Administration, Oral
Share to Angioplasty, Balloon, Coronary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Drug Monitoring

Share to Platelet Function Tests

Share to Purinergic P2Y Receptor Antagonists

Share to Ticlopidine

Source

Identifiers

PMID: 24378839
DOI: 10.2459/JCM.0b013e328364bd25

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.PMID 24378839Read ↗

Response variability to P2Y12 receptor inhibitors: expectations and reality.Semantic proximity Read ↗

Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.Semantic proximity Read ↗

P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.Semantic proximity Read ↗

High platelet reactivity and clinical outcome - fact and fiction.Semantic proximity Read ↗

Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.Semantic proximity Read ↗

International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update.Semantic proximity Read ↗

Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrelSemantic proximity Read ↗

Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms.Semantic proximity Read ↗

Baseline P2Y12 reactivity, kidney function, and CYP2C19 genotype determine clopidogrel responsiveness in acute stroke.Semantic proximity Read ↗

Most Recent Evidence Behind Aggregometry and Genotyping Methods as Platelet Function Testing for Tailored Anti-Platelet Treatment Among PCI Patients.Semantic proximity Read ↗

Personalized antiplatelet therapy: a scoping review on the role of platelet function testing and genotyping in acute coronary syndrome.Semantic proximity Read ↗

Pharmacogenetics of P2Y 12 receptor inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.